ARECOR THERAPEUTICS PLC — Director's Dealing 2021

Oct 25, 2021

National Storage Mechanism | Additional information

RNS Number : 1835Q

Arecor Therapeutics PLC

25 October 2021

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

Exercise of options, PDMR dealing and Total Voting Rights

Cambridge, UK, 25 October 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, announces that it has issued and allotted 151,492 new Ordinary Shares of 1 pence each in the share capital of the Company following an exercise of options on 25 October 2021 at an exercise price of 1 pence per Ordinary Share. The options exercised were part of the rollover of share options previously granted under the historic Arecor Limited EMI Share Option Plan 2018 ("Option Rollover"). Details of the Option Rollover are set out in the Company's Admission Document.

Included in the exercise of options were options over 123,336 ordinary shares held by Directors/PDMRs of the Company as detailed in the table below:

Director/ PDMR	Position	Existing interest in Ordinary Shares	Number of Options over Ordinary Shares exercised	Resultant interest in Ordinary Shares	Options remaining after exercise
David Gerring	VP, Development	142,956	8,336	151,292	83,334
Sarah Howell	Chief Executive Officer	788,742	51,664	840,406	360,666
Jan Jezek	Chief Scientific Officer	396,138	8,336	404,474	163,334
Fiona Lawrence	VP, Clinical & Regulatory Affairs	66,168	4,166	70,334	81,666
Susan Lowther	Chief Financial Officer	110,681	25,834	136,515	322,000
James MacDonald-Clink	VP, Business Development	-	25,000	25,000	105,000

Admission

Following the above transactions, application has been made for the 151,492 new Ordinary Shares to be admitted to trading on AIM ("Admission") and dealings are expected to commence on, or around, 29 October 2021. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 27,835,024. Accordingly, the figure of 27,835,024 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: +44 (0) 1223 426060 Email: info@arecor.com
Susan Lowther, Chief Financial Officer	Tel: +44 (0) 1223 426060 Email: info@arecor.com
Mo Noonan, Communications	Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: +44 (0) 20 7886 2500
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray	Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat ™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

a)  David Gerring

b)  Sarah Howell

c)  Jan Jezek

d)  Fiona Lawrence

e)  Susan Lowther

f)  James MacDonald-Clink

2. 

Reason for the notification

a)

Position/status:

a)  VP, Development

b)  Chief Executive Officer

c)  Chief Scientific Officer

d)  VP, Clinical & Regulatory Affairs

e)  Chief Financial Officer

f)  VP, Business Development

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics PLC

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Exercise of options over ordinary shares

c)

Price(s) and volume(s):

Price(s)	Volume(s)
a) £0.01	a) 8,336
b) £0.01	b) 51,664
c) £0.01	c) 8,336
d) £0.01	d) 4,166
e) £0.01	e) 25,834
f) £0.01	f) 25,000

d)

Aggregated information:

· Aggregated volume:

· Price:

123,336

£0.01

e)

Date of the transaction:

25 October 2021

f)

Place of the transaction:

London Stock Exchange, AIM Market (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUBDGXDDDGBU